Detrusor relaxing agents for neurogenic detrusor overactivity: a systematic review, meta‐analysis and network meta‐analysis

Abstract

ObjectiveTo evaluate the evidence regarding the therapeutic benefits and safety of oral detrusor relaxing agents (DRAs) in treating neurogenic detrusor overactivity (NDO).MethodsA comprehensive search was performed on 1 September 2022. Two authors independently reviewed the articles to extract data using a pre‐designed form. The meta‐analysis was performed following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. A common‐effect or random‐effects model was used based on the heterogeneity among studies. Bayesian network meta‐analysis (NMA) was further performed to make indirect comparisons of antimuscarinics and mirabegron.ResultsA total of 23 randomised controlled trials (RCTs) comprising 1697 patients were included in our analysis. Compared to placebo, the clinical benefits of oral DRAs, along with more adverse events (AEs), were demonstrated in the treatment of NDO. In the subgroup analysis, antimuscarinics significantly improved both urodynamic and bladder diary outcomes (including urinary incontinence episodes, urinary frequency, and residual volume), with a higher rate of AEs, such as xerostomia. Mirabegron improved some of the parameters and had fewer bothersome side‐effects in patients with NDO. The NMA showed that none of the antimuscarinics or mirabegron was superior or inferior to the other.ConclusionsDetrusor relaxing agents are associated with improved outcomes in patients with NDO and our analysis has added new evidence regarding antimuscarinics. Evidence concerning mirabegron as first‐line therapy for NDO is still limited. Well‐designed RCTs are still required in this specific population.